Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
238,4 CHF | +0,68% | +0,25% | -8,72% |
13:58 | Roche's medicijn tegen longkanker Alecensa goedgekeurd in EU | MT |
25/04 | Scholz belooft verdere steun voor farmaceutische industrie | DP |
Omzet 2024 * | 60,04 mld. 65,81 mld. 61,33 mld. | Omzet 2025 * | 63,83 mld. 69,97 mld. 65,21 mld. | Marktkapitalisatie | 176 mld. 193 mld. 180 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 13,31 mld. 14,59 mld. 13,6 mld. | Nettowinst (verlies) 2025 * | 14,75 mld. 16,17 mld. 15,07 mld. | EV/omzet 2024 * | 3,17 x |
Nettoschuld 2024 * | 14,24 mld. 15,61 mld. 14,55 mld. | Nettoschuld 2025 * | 8,17 mld. 8,95 mld. 8,34 mld. | EV/omzet 2025 * | 2,89 x |
K/w-verhouding 2024 * |
12,9
x | K/w-verhouding 2025 * |
11,7
x | Werknemers | 103.605 |
Dividendrendement 2024 * |
4,44% | Dividendrendement 2025 * |
4,6% | Vrij verhandelbaar | 88,91% |
Recentste transcriptie over Roche Holding AG
1 dag | +0,59% | ||
1 week | +0,25% | ||
Lopende maand | -1,81% | ||
1 maand | -0,50% | ||
3 maanden | -9,48% | ||
6 maanden | -4,64% | ||
Lopend jaar | -8,72% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 49 | 01-01-03 | |
Severin Schwan
CHM | Chairman | 57 | 01-01-08 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 01-04-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 03-03-15 |
Director/Board Member | 59 | - | |
Director/Board Member | 65 | 01-01-96 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
2.06% | 2 M€ | -.--% | - | |
2.06% | 2 M€ | +9,19% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 238,6 | +0,76% | 9 890 |
25-04-24 | 236,8 | -1,00% | 41 602 |
24-04-24 | 239,2 | -4,40% | 32 173 |
23-04-24 | 250,2 | +2,46% | 49 199 |
22-04-24 | 244,2 | +2,61% | 41 027 |
uitgestelde koers Swiss Exchange, 26 april 2024 om 14:38 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+24,35% | 653 mld. | |
+25,48% | 556 mld. | |
-6,33% | 354 mld. | |
+19,90% | 331 mld. | |
+7,95% | 296 mld. | |
+12,98% | 233 mld. | |
+5,35% | 201 mld. | |
-6,47% | 144 mld. | |
-12,26% | 143 mld. |